Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988830 | 0.82 | XDH (0.35) | KDM4EGDACYP3A4MAPK1PMP22 | |
| SCHEMBL2456941 | 0.70 | NR1H2 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL12102064 | 0.67 | TNKS2 (0.36) | — | |
| SCHEMBL25080175 | 0.63 | PARP1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL7603458 | 0.62 | PDE2A (0.36) | PDE2AMAPK1 | |
| SCHEMBL7981200 | 0.61 | POLB (0.51) | KDM4EPDE2AALDH1A1PDE4APDE4B | |
| SCHEMBL18711844 | 0.61 | SPR (0.41) | — | |
| SCHEMBL11803855 | 0.59 | — | — | |
| SCHEMBL16651757 | 0.59 | BRD4 (0.41) | KDM4E | |
| SCHEMBL22477775 | 0.59 | TRPA1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | LEXICON GENETICS INCORPORATED | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287293-B2 | Bicyclic heterocyclic compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | KDM4E 3056/4885GDA 252/4885PDE2A 1/4885 |
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | KDM4E 3056/4885GDA 252/4885PDE2A 1/4885 |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | PDE3A, PDE2A, PDE3B | KDM4E 744/4885GDA 644/4885PDE2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.